| Oral selinexor–dexamethasone for triple-class refractory multiple myeloma A Chari, DT Vogl, M Gavriatopoulou, AK Nooka, AJ Yee, CA Huff, ... New England Journal of Medicine 381 (8), 727-738, 2019 | 608 | 2019 |
| Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma J Richter, N Neparidze, L Zhang, S Nair, T Monesmith, R Sundaram, ... Blood, The Journal of the American Society of Hematology 121 (3), 423-430, 2013 | 179 | 2013 |
| Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma DT Vogl, D Dingli, RF Cornell, CA Huff, S Jagannath, D Bhutani, J Zonder, ... Journal of clinical oncology 36 (9), 859, 2018 | 165 | 2018 |
| A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward B Wang, O Van Oekelen, TH Mouhieddine, DM Del Valle, J Richter, ... Journal of hematology & oncology 13, 1-12, 2020 | 144 | 2020 |
| Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM … S Trudel, AD Cohen, AY Krishnan, R Fonseca, A Spencer, JG Berdeja, ... Blood 138, 157, 2021 | 118 | 2021 |
| COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers M Hultcrantz, J Richter, CA Rosenbaum, D Patel, EL Smith, N Korde, ... Blood cancer discovery 1 (3), 234-243, 2020 | 83 | 2020 |
| Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials M Gavriatopoulou, A Chari, C Chen, N Bahlis, DT Vogl, A Jakubowiak, ... Leukemia 34 (9), 2430-2440, 2020 | 82 | 2020 |
| Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group NS Raje, E Anaissie, SK Kumar, S Lonial, T Martin, MA Gertz, A Krishnan, ... The Lancet Haematology 9 (2), e143-e161, 2022 | 81 | 2022 |
| Bispecific antibodies in multiple myeloma: present and future G Lancman, DL Sastow, HJ Cho, S Jagannath, D Madduri, SS Parekh, ... Blood cancer discovery 2 (5), 423-433, 2021 | 74 | 2021 |
| Venetoclax induces deep hematologic remissions in t (11; 14) relapsed/refractory AL amyloidosis VJ Premkumar, S Lentzsch, S Pan, D Bhutani, J Richter, S Jagannath, ... Blood cancer journal 11 (1), 10, 2021 | 66 | 2021 |
| Blood transfusion management for patients treated with anti-CD38 monoclonal antibodies G Lancman, S Arinsburg, J Jhang, HJ Cho, S Jagannath, D Madduri, ... Frontiers in immunology 9, 2616, 2018 | 66 | 2018 |
| Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges MV Dhodapkar, J Richter Clinical immunology 140 (2), 160-166, 2011 | 63 | 2011 |
| Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications S Bhalla, DT Melnekoff, A Aleman, V Leshchenko, P Restrepo, J Keats, ... Science advances 7 (47), eabg9551, 2021 | 60 | 2021 |
| Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy O Van Oekelen, K Nath, TH Mouhieddine, T Farzana, A Aleman, ... Blood 141 (7), 756-765, 2023 | 53 | 2023 |
| Selinexor in relapsed/refractory multiple myeloma J Richter, D Madduri, S Richard, A Chari Therapeutic Advances in Hematology 11, 2040620720930629, 2020 | 49 | 2020 |
| A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma J Mikhael, J Richter, R Vij, C Cole, J Zonder, JL Kaufman, W Bensinger, ... Leukemia 34 (12), 3298-3309, 2020 | 48 | 2020 |
| Bispecifics, trispecifics, and other novel immune treatments in myeloma G Lancman, J Richter, A Chari Hematology 2014, the American Society of Hematology Education Program Book …, 2020 | 44 | 2020 |
| Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study AM Lesokhin, J Richter, S Trudel, AD Cohen, A Spencer, PA Forsberg, ... Blood 140 (Supplement 1), 4415-4417, 2022 | 42 | 2022 |
| Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM). JR Richter, TG Martin, R Vij, C Cole, D Atanackovic, JA Zonder, ... Journal of Clinical Oncology 34 (15_suppl), 8005-8005, 2016 | 39 | 2016 |
| A dose finding phase II trial of isatuximab (SAR650984, anti-CD38 mAb) as a single agent in relapsed/refractory multiple myeloma T Martin, J Richter, R Vij, C Cole, D Atanackovic, J Zonder, JL Kaufman, ... Blood 126 (23), 509, 2015 | 39 | 2015 |
